Recruiting studies: Lymphoma Large B Cell Diffuse Dlbcl

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
Phase 1 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06464861 Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Phase N/A · 7 location(s) · Novartis Pharmaceuticals · NCT05541341 Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05757219 Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Phase N/A · 1 location(s) · Ain Shams University · NCT07057765 Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06682130 A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel The
Phase N/A · 21 location(s) · AstraZeneca · NCT07065344 Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06043011 Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116 CHiR Therapy for Elderly DLBCL Intolerant to Chemo
Phase 2 · 1 location(s) · First Affiliated Hospital of Ningbo University · NCT06764017 R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
Phase 2 · 2 location(s) · Fudan University · NCT05257018 Long-term Follow up Local Registry Study of Kymriah in South Korea
Phase N/A · 16 location(s) · Novartis Pharmaceuticals · NCT06785818 The CARDIOPROTECT Trial
Phase 2 · 1 location(s) · Beth Israel Deaconess Medical Center · NCT07654426 IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Phase 1 · 13 location(s) · Iksuda Therapeutics Ltd. · NCT05365659 Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
Phase 1 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT07478848 Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantati
Phase 2 · 1 location(s) · The Affiliated Hospital of Xuzhou Medical University · NCT07680933 A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Phase 1/Phase 2 · 21 location(s) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · NCT07124936 A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Phase 3 · 50 location(s) · Hutchmed · NCT07409428 Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy
Phase 3 · 49 location(s) · Fondazione Italiana Linfomi - ETS · NCT04442412 Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
Phase 2 · 1 location(s) · Rong Tao · NCT07507318 Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
EARLY_Phase 1 · 1 location(s) · He Huang · NCT06120166 Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
Phase 2 · 7 location(s) · University Medical Center Groningen · NCT05641428 Pola-ZR2P in Previously Untreated DLBCL
Phase 2 · 1 location(s) · Navy General Hospital, Beijing · NCT06664411 A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Accutar Biotechnology Inc · NCT05780034 Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola
Phase 2 · 1 location(s) · Fudan University · NCT07001540 Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
Phase 2 · 11 location(s) · Sun Yat-sen University · NCT06647940 Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1 · 36 location(s) · Schrödinger, Inc. · NCT05544019 Real-World Study of DLBCL With Different Genetic Subtypes
Phase N/A · 1 location(s) · Ruijin Hospital · NCT06026488 Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/Phase 2 · 34 location(s) · Lyell Immunopharma, Inc. · NCT05826535 DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refrac
Phase 2 · 50 location(s) · ImmunoVaccine Technologies, Inc. (IMV Inc.) · NCT04920617 Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseli
Phase 2 · 1 location(s) · Liling Zhang · NCT06867536

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.